SAB Biotherapeutics and Alumend To Anchor USD Discovery District


SAB Biotherapeutics and Alumend will be the anchor tenants for the the University of South Dakota Discovery District, USD and the Governor’s Office of Economic Development announced on Monday. 

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human antibody therapeutics using first-of-its-kind immunotherapy platform leveraging transgenic cattle. The company, which has doubled in size since its founding in 2014, will hold its corporate headquarters, research laboratories and cGMP biomanufacturing suite at the site. 

Alumend LLC, Avera’s applied research and development company, will establish its corporate office and research laboratory in the district. Alumend scientists have developed Natural Vascular Scaffolding therapy, a novel drug/device combination for the treatment of peripheral vascular disease. 

The Discovery District is an 80-acre corporate and academic research park across to the University Center in northwest Sioux Falls. The $30.9 million project will feature South Dakota’s first commercial Current Good Manufacturing Practice biotherapeutics manufacturing facility.

The first new building will be an 84,000 square-foot multi-tenant reseach lab, office and biopharmaceutical manufacturing space, which will host SAB Biotherapeutics and Alumend as well as USD Discovery District offices along with 20,000 square-feet of leasable space.

The second building is a 42,000 square-foot commercial biomanufacturing production facility, where SAB plans to use the building for its commercial biotherapeutics production operations. 

Gov. Dennis Daugaard, Sioux Falls Mayor Paul TenHaken, USD President Jim Abbott, President of the USD Discovery District Rich Naser along with SAB Biotherapeutics co-founders Eddie and Christine Hamilton and Avera Research Institute Executive Director Ryan Hansen attended the announcement on Monday.  

The goal is break ground in fall 2018 and have the first building completed by 2020. 

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories


Don't Miss!

More Don't Miss

Our Contests

More Contests